The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma
Sponsor: Bristol-Myers Squibb
A PHASE2 clinical study on HIV Infections and Sarcoma, Kaposi, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- National Institute of Allergy and Infectious Diseases (NIAID)
- Schering-Plough
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aurora, United States, Boston, United States, Buffalo, United States, Chicago, United States, Cincinnati, United States, Indianapolis, United States, New York, United States, Palo Alto, United States, Philadelphia, United States, San Juan, Puerto Rico and 1 more location